TORONTO, Nov. 2, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and proposed manufacture of novel or generic controlled release and targeted release oral solid dosage drugs, today announced that the Company received a letter on October 29, 2010 from NASDAQ, stating that Intellipharmaceutics is not in compliance with NASDAQ's 'minimum stockholders' equity' continued listing requirement of $2.5 million under NASDAQ Listing Rule 5550(b)(1). As of August 31, 2010, Intellipharmaceutics' stockholders' equity was approximately $1.8 million.
Intellipharmaceutics NASDAQ Update And Corporate Matters
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.